Lindbrook Capital’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-461
| Closed | -$7.25K | – | 2852 |
|
|
2024
Q1 | $7.25K | Hold |
461
| – | – | ﹤0.01% | 1729 |
|
|
2023
Q4 | $7.44K | Buy |
461
+95
| +26% | +$1.21K | ﹤0.01% | 1689 |
|
|
2023
Q3 | $4.66K | Hold |
366
| – | – | ﹤0.01% | 1802 |
|
|
2023
Q2 | $5.15K | Hold |
366
| – | – | ﹤0.01% | 1793 |
|
|
2023
Q1 | $5.66K | Sell |
366
-103
| -22% | -$1.72K | ﹤0.01% | 1800 |
|
|
2022
Q4 | $7.69K | Sell |
469
-50
| -10% | -$813 | ﹤0.01% | 1563 |
|
|
2022
Q3 | $10K | Buy |
519
+50
| +11% | +$785 | ﹤0.01% | 1354 |
|
|
2022
Q2 | $6K | Buy |
469
+327
| +230% | +$3.61K | ﹤0.01% | 1509 |
|
|
2022
Q1 | $1K | Buy |
+142
| New | +$1.21K | ﹤0.01% | 2427 |
|
|
2021
Q3 | – | Sell |
-106
| Closed | -$4K | – | 2033 |
|
|
2021
Q2 | $4K | Buy |
106
+99
| +1,414% | +$3.83K | ﹤0.01% | 1418 |
|
|
2021
Q1 | $0 | Hold |
7
| – | – | ﹤0.01% | 1957 |
|
|
2020
Q4 | $0 | Hold |
7
| – | – | ﹤0.01% | 1902 |
|
|
2020
Q3 | $0 | Hold |
7
| – | – | ﹤0.01% | 1864 |
|
|
2020
Q2 | $0 | Sell |
7
-17
| -71% | -$909 | ﹤0.01% | 1918 |
|
|
2020
Q1 | $1K | Buy |
+24
| New | +$1.33K | ﹤0.01% | 1608 |
|
Other funds holding DCPH
Lindbrook Capital's DCPH Position: Q2 2024 in Review
Lindbrook Capital sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 461 shares — an estimated $7.25K sold.
Lindbrook Capital first reported a position in DCPH in Q1 2020 and held it in 15 quarters. The position peaked at $10K in Q3 2022. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- Lindbrook Capital reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Lindbrook Capital sold 461 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $7.25K.
- Lindbrook Capital first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 15 quarters.
- Lindbrook Capital's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $10K in Q3 2022.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Lindbrook Capital's 13F filing for Q2 2024, filed 31 Jul 2024.